Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status

[Display omitted] SARS-CoV-2 is causing an increasing number of deaths worldwide because no effective treatment is currently available. Remdesivir has shown in vitro activity against coronaviruses and is a possible antiviral treatment for SARS-CoV-2 infection. This prospective (compassionate), open-...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmacological research 2020-08, Vol.158, p.104899-104899, Article 104899
Hauptverfasser:	Antinori, Spinello, Cossu, Maria Vittoria, Ridolfo, Anna Lisa, Rech, Roberto, Bonazzetti, Cecilia, Pagani, Gabriele, Gubertini, Guido, Coen, Massimo, Magni, Carlo, Castelli, Antonio, Borghi, Beatrice, Colombo, Riccardo, Giorgi, Riccardo, Angeli, Elena, Mileto, Davide, Milazzo, Laura, Vimercati, Stefania, Pellicciotta, Martina, Corbellino, Mario, Torre, Alessandro, Rusconi, Stefano, Oreni, Letizia, Gismondo, Maria Rita, Giacomelli, Andrea, Meroni, Luca, Rizzardini, Giuliano, Galli, Massimo
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Kidney Injury - chemically induced Adenosine Monophosphate - adverse effects Adenosine Monophosphate - analogs & derivatives Adenosine Monophosphate - therapeutic use Aged Alanine - adverse effects Alanine - analogs & derivatives Alanine - therapeutic use Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Betacoronavirus Compassionate Use Trials - statistics & numerical data Coronavirus Infections - blood Coronavirus Infections - drug therapy COVID-19 Female Hospitalization - statistics & numerical data Humans Intensive Care Units - statistics & numerical data Male Middle Aged Pandemics Pneumonia, Viral - blood Pneumonia, Viral - drug therapy Remdesivir SARS-CoV-2 Transaminases - blood Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!